Efficacy of Transarterial Chemolipiodolization with or without 3-Dimensional Conformal Radiotherapy for Huge HCC with Portal Vein Tumor Thrombosis.
10.3350/kjhep.2007.13.3.378
- Author:
Chan Ran YOU
1
;
Jeong Won JANG
;
Seok Hui KANG
;
Si Hyun BAE
;
Jong Young CHOI
;
Seung Kew YOON
;
Ihl Bhong CHOI
;
Dong Hoon LEE
;
Ho Jong CHUN
;
Byung Gil CHOI
Author Information
1. Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. bash@catholic.ac.kr
- Publication Type:Original Article ; Comparative Study ; English Abstract
- Keywords:
Carcinoma, hepatocellular;
Portal vein tumor thrombosis (PVTT);
Radiotherapy, conformal;
Transarterial chemolipiodolization (TACL);
Treatment outcome
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Carcinoma, Hepatocellular/complications/radiotherapy/*therapy;
Chemoembolization, Therapeutic/*methods;
Combined Modality Therapy;
Data Interpretation, Statistical;
Female;
Humans;
Liver Neoplasms/complications/radiotherapy/*therapy;
Male;
Middle Aged;
*Portal Vein;
Radiotherapy, Conformal/adverse effects/*methods;
Severity of Illness Index;
Survival Analysis;
Venous Thrombosis/etiology/radiotherapy/*therapy
- From:The Korean Journal of Hepatology
2007;13(3):378-386
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: The treatment efficacy for advanced hepatocellular carcinoma is poor. This study examined the efficacy and toxicity of 3-dimensional conformal radiotherapy (3D-CRT) in combination with transarterial chemolipiodolization (TACL) for a huge hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). METHODS: From March 2001 to November 2004, 49 patients with advanced HCC with PVTT (size>8 cm, modified UICC stage IVa) were enrolled in this retrospective study. Twenty two patients underwent more than 2 cycles of TACL (adriamycin 50 mg/m2, cisplatin 60 mg/m2, 5-fluorouracil 200 mg/m2 every 4-6 weeks) without 3D-CRT, while 27 patients underwent consecutive TACL with 3D-CRT (40-45 Gy for 4-5 weeks) that was started one week after the 1st TACL. The response was assessed by a computed tomography (CT) and the serum alpha-fetoprotein (AFP) level at 1-2 month intervals. RESULTS: The objective response rates in the TACL group and TACL with 3D-CRT group were 18% and 48% at 3 months (P=0.051), and 10.5% and 42% at 6 months (P=0.024) respectively. The median survival time was 13 months and 13.5 months in TACL and TACL with 3D-CRT groups, respectively (P=0.502). The treatment response was better in the TACL with 3D-CRT group but there was no significant difference in survival between the two groups. Most toxicities in the two groups were mild, not exceeding grade 1 according to the WHO criteria. CONCLUSIONS: For patients with a huge HCC with PVTT, TACL with 3D-CRT achieved some meaningful clinical benefit. Prospective controlled trials will be needed to confirm the real benefit of TACL combined with 3D-CRT.
